

Are your **MRI contrast agents** cost-effective?

Learn more about generic **Gadolinium-Based Contrast Agents**.



**AJNR**

**Diffusion-Weighted Imaging of Orbital Masses: Multi-Institutional Data Support a 2-ADC Threshold Model to Categorize Lesions as Benign, Malignant, or Indeterminate**

This information is current as of April 18, 2024.

A.R. Sepahdari, L.S. Politi, V.K. Aakalu, H.J. Kim and A.A.K. Abdel Razek

*AJNR Am J Neuroradiol* 2014, 35 (1) 170-175

doi: <https://doi.org/10.3174/ajnr.A3619>

<http://www.ajnr.org/content/35/1/170>

# Diffusion-Weighted Imaging of Orbital Masses: Multi-Institutional Data Support a 2-ADC Threshold Model to Categorize Lesions as Benign, Malignant, or Indeterminate

A.R. Sepahdari, L.S. Politi, V.K. Aakalu, H.J. Kim, and A.A.K. Abdel Razek



## ABSTRACT

**BACKGROUND AND PURPOSE:** DWI has been increasingly used to characterize orbital masses and provides quantitative information in the form of the ADC, but studies of DWI of orbital masses have shown a range of reported sensitivities, specificities, and optimal threshold ADC values for distinguishing benign from malignant lesions. Our goal was to determine the optimal use of DWI for imaging orbital masses through aggregation of data from multiple centers.

**MATERIALS AND METHODS:** Source data from 3 previous studies of orbital mass DWI were aggregated, and additional published data points were gathered. Receiver operating characteristic analysis was performed to determine the sensitivity, specificity, and optimal ADC thresholds for distinguishing benign from malignant masses.

**RESULTS:** There was no single ADC threshold that characterized orbital masses as benign or malignant with high sensitivity and specificity. An ADC of less than  $0.93 \times 10^{-3} \text{ mm}^2/\text{s}$  was more than 90% specific for malignancy, and an ADC of less than  $1.35 \times 10^{-3} \text{ mm}^2/\text{s}$  was more than 90% sensitive for malignancy. With these 2 thresholds, 33% of this cohort could be characterized as “likely malignant,” 29% as “likely benign,” and 38% as “indeterminate.”

**CONCLUSIONS:** No single ADC threshold is highly sensitive and specific for characterizing orbital masses as benign or malignant. If we used 2 thresholds to divide these lesions into 3 categories, however, a majority of orbital masses can be characterized with >90% confidence.

**ABBREVIATIONS:** ROC = receiver operating characteristic analysis

Orbital space-occupying lesions represent a heterogeneous group that includes benign tumors, malignant tumors, inflammatory lesions, vascular lesions, and infections.<sup>1</sup> Frequent nonclassic clinical presentations, challenging pathologic evaluation, and risks associated with biopsy are strong reasons to develop better noninvasive diagnostic and imaging tools for orbital disease.

Imaging with CT and MR can be helpful in establishing a diagnosis through demonstration of characteristic patterns of ana-

tomous involvement and through features such as CT attenuation, MR imaging signal intensity, and pattern of contrast enhancement.<sup>2-9</sup> Nevertheless, imaging is frequently nonspecific, and significant room for improvement remains in imaging diagnosis.

DWI has been increasingly used to characterize solid masses in the head and neck, aiding in the distinction of benign and malignant lesions.<sup>10</sup> Several retrospective studies have characterized orbital masses with DWI, and some have attempted to determine optimal quantitative ADC thresholds and their sensitivity and specificity in distinguishing malignant from benign lesions.<sup>11-18</sup> These studies have shown somewhat conflicting results and have been limited by single-institution designs and potential selection bias inherent to their patient populations. Specifically, some studies have suggested that a single ADC threshold can be both highly sensitive and specific for predicting malignancy,<sup>16</sup> whereas other results have contradicted this statement.<sup>11,14</sup>

To resolve these outstanding conflicts, we performed an analysis of aggregated data by using all available published data points on the DWI of orbital masses, including aggregated source data from the 3 largest published case series on this topic.<sup>14,16,17</sup> The

Received January 23, 2013; accepted after revision April 9.

From the Department of Radiological Sciences (A.R.S., H.J.K.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; Department of Neuroradiology (L.S.P.), San Raffaele Institute of Science, Milan, Italy; Department of Ophthalmology and Visual Sciences (V.K.A.), University of Illinois at Chicago, Chicago, Illinois; and Diagnostic Radiology Department (A.A.K.A.R.), Mansoura Faculty of Medicine, Mansoura, Egypt.

No conflicting relationship exists for any author.

Please address correspondence to Ali R. Sepahdari, MD, 757 Westwood Plaza, Suite 1621D, Los Angeles, CA 90095; e-mail: asephadari@mednet.ucla.edu; ali.sephadari@gmail.com

Indicates article with supplemental on-line table.

<http://dx.doi.org/10.3174/ajnr.A3619>

purpose of this study was to better determine what ADC thresholds can be used to predict either benign or malignant histology with high confidence.

## MATERIALS AND METHODS

### Review of Published Literature

To conduct an initial meta-analysis, the lead author (A.R.S.) performed a MEDLINE search to identify published data on the DWI of orbital masses. The search strings included “orbit” OR “orbital” AND “DWI” OR “diffusion-weighted,” as well as “head and neck” AND “DWI” OR “diffusion-weighted.” One hundred forty-three results were obtained, as of February 2013. These were reviewed, and studies that did not describe the DWI of orbital space-occupying lesions were excluded, leaving 11 studies. Studies of exclusively intraocular tumors and of demyelinating optic neuritis were excluded in this process. Of these 11, one was excluded because its data were wholly duplicated in a more expansive follow-up study from the same authors. The remaining 10 studies, which described 260 orbital masses, were further analyzed.<sup>11,12,14,16,17,19-23</sup> The lesions described in each of these studies were characterized as either lymphoma, metastasis, nonlymphomatous primary malignancy, benign mass, inflammatory disease, vascular malformation, or infection. The distribution of lesions across the studies is summarized in the On-line Table.

The review of the literature revealed only 2 studies that reported sufficient quantitative metrics (sensitivity, specificity, positive predictive value, negative predictive value) to permit meta-analysis, both from this study’s authors.<sup>14,16</sup> It was not possible to reconstruct these data from the published results of the other studies, either because of a small sample size or the way the data were summarized. In place of a meta-analysis, we attempted to aggregate as many raw data points as could be obtained on the basis of source data from the study authors’ previous works and ADC values of individual tumors that could be obtained from the literature. All tumors with reported ADC values were included. In some cases, multiple lesions with the same diagnosis were reported as an average and SD of the group. These data were excluded from further analysis because it was impossible to incorporate them into the receiver operating characteristic analysis (ROC). To assess for a systematic bias in lesion distribution, we compared the distribution of lesions from the published data and from the final analysis group against historical data from the largest published series of orbital masses by Shields et al.<sup>1</sup> These data are summarized in Table 1.

### Data Collection and Analysis

The de-identified data used in this study comprised source data from 3 previously published case series of orbital mass DWI by the authors of this study, consisting of ADC and corresponding clinical/pathologic diagnosis for 189 cases.<sup>14,16,17</sup> These data were collected with the approval of the respective local institutional review boards/ethics committees, with technical methods as previously described.<sup>14,16,17</sup> Thirteen additional orbital mass ADC values were obtained through review of the literature. In total, 98 benign lesions and 104 malignant masses were studied. The re-

**Table 1: Distribution of lesions by category in published studies of DWI, analysis group of this study, and in the largest reported clinical series by Shields et al, 2004<sup>a</sup>**

	Pre-Exclusion		
	Published Data of Orbital DWI	Final Analysis Group	Shields et al, 2004
Lymphoma	57	46	123
Metastasis	21	20	91
Malignant primary	50	38	219
Benign primary	51	27	182
Inflammatory	48	39	193
Vasculogenic	25	24	169
Infection	8	8	13

<sup>a</sup> Any lesions from the Shields et al<sup>1</sup> series that were likely to be excluded in studies of orbital DWI were removed. Capillary hemangioma was categorized as a benign primary tumor, reflecting current understanding. Nonmalignant lymphocytic or histiocytic processes were categorized as inflammatory disease.

maining 58 cases were excluded either because quantitative ADC analysis was not performed by the original authors or because the data were reported in a summarized fashion that did not allow the extraction of individual data points.

The data included DWI studies performed on MR imaging machines from different vendors, with different field strengths and different technical parameters. To determine the equivalence of the DWI techniques across institutions, we compared the most commonly occurring lesions across the authors’ source datasets with each other by using Kruskal-Wallis analysis. Lymphomas from the 3 source datasets (6, 32, and 6 tumors) and inflammatory lesions from the 3 source datasets (20, 13, and 6 lesions) were compared.

The data were then grouped into benign and malignant categories. For each of these categories, descriptive statistics, Student *t* tests, and ROC were performed. These analyses were performed for all lesions in aggregate and for the authors’ source datasets separately. Sensitivity and specificity of various ADC thresholds for distinguishing benign from malignant masses were determined.

Lymphoma and inflammatory lesions were also compared with each other separately because there is considerable clinical and radiologic overlap in these conditions. As mentioned above, descriptive statistics, Student *t* tests, and ROC were performed.

In consideration of the disproportionately large number of lymphoma lesions in our dataset, which may skew the results through characteristically low ADC, ROC was also performed, comparing benign lesions and malignant tumors, after excluding lymphomas.

## RESULTS

### Lesions Analyzed

The final analysis group consisted of 202 patients with 98 benign lesions and 104 malignant lesions. The most common benign lesions were inflammatory masses ( $n = 39$ ), vascular lesions ( $n = 24$ ), and optic nerve sheath meningiomas ( $n = 11$ ). The most common malignant lesions were lymphoma ( $n = 46$ ) and metastases ( $n = 20$ ). The data are summarized in Table 2. The composition of the final analysis group of 202 subjects was similar to the composition of the 260 subjects imaged with DWI before exclusion of unavailable data points (Table 1 and Fig 1), though with a modest reduction in the proportion of benign primary lesions.

Both groups contained a larger proportion of lymphoma lesions than would be expected on the basis of available epidemiologic data.<sup>1</sup> When lymphomas were excluded, the composition of the pre-exclusion group, final analysis group, and the epidemiologic data was similar (Fig 1).

### Validation of ADC across Techniques

There was no significant difference in the ADC of lymphoma across the authors' source datasets ( $P = .98$ ). Likewise, there was no significant difference in ADC of inflammatory lesions across these datasets ( $P = .42$ ). These data are summarized in Table 2.

**Table 2: Summarized ADC values of commonly occurring lesions**

Lesion (No.)	ADC ( $10^{-3} \text{ mm}^2/\text{s}$ ) (mean $\pm$ SD)	Range
Benign (98)	1.42 $\pm$ 0.41	0.72–2.78
Inflammatory (39)	1.40 $\pm$ 0.31	0.93–2.28
Cavernous hemangioma (ie, encapsulated venous malformation) (12)	1.23 $\pm$ 0.20	0.73–1.44
Optic nerve sheath meningioma (11)	0.99 $\pm$ 0.20	0.56–1.28
Other vascular (15)	1.58 $\pm$ 0.40	0.98–2.26
Other benign (22)	1.67 $\pm$ 0.51	1.00–2.78
Malignant (104)	0.90 $\pm$ 0.37	0.34–2.08
Lymphoma (46)	0.66 $\pm$ 0.09	0.44–0.91
Metastasis (20)	1.20 $\pm$ 0.31	0.64–2.08
Rhabdomyosarcoma (12)	0.72 $\pm$ 0.31	0.34–1.31
Carcinoma (9)	1.15 $\pm$ 0.12	1.04–1.39
Other malignant (17)	1.19 $\pm$ 0.47	0.34–2.12

### Descriptive Characteristics


Benign lesions showed an ADC of  $1.43 \pm 0.41 \times 10^{-3} \text{ mm}^2/\text{s}$  (mean). Malignant lesions showed ADC of  $0.90 \pm 0.36 \times 10^{-3} \text{ mm}^2/\text{s}$  (Table 3). Figure 2 shows a scatterplot of lesion categories with corresponding ADCs. There were significant differences between benign and malignant lesions with respect to ADC ( $P < .0001$ ), and these differences were visually apparent (Fig 3). Significant differences remained ( $P < .0001$ ), even after exclusion of lymphomas.

### ADC Performance in Distinguishing Benign from Malignant Lesions

The area under the ROC curve for aggregated data was 0.84. An ADC threshold of less than  $0.93 \times 10^{-3} \text{ mm}^2/\text{s}$  resulted in a 60% sensitivity and 96% specificity for malignancy. A more lenient threshold of ADC less than  $1.35 \times 10^{-3} \text{ mm}^2/\text{s}$  resulted in 90% sensitivity for malignancy, but only 49% specificity. When lymphomas were excluded, the area under the ROC curve dropped to 0.73. The  $0.93 \times 10^{-3} \text{ mm}^2/\text{s}$  threshold resulted in only a 28% sensitivity for malignancy, with a 96% specificity. Figure 4 shows the ROC curve for distinguishing benign from malignant lesions. Table 4 shows the sensitivities and specificities of various ADC values for distinguishing benign from malignant lesions.

### ADC Performance in Distinguishing Lymphoma from Inflammatory Disease

Lymphomas showed an ADC of  $0.67 \pm 0.09 \times 10^{-3} \text{ mm}^2/\text{s}$ . Inflammatory lesions showed an ADC of  $1.40 \pm 0.31 \times 10^{-3} \text{ mm}^2/\text{s}$ . There was no overlap between lymphoma and inflammatory lesions. Only 2 of 46 lymphomas had an ADC of greater than  $0.8 \times 10^{-3} \text{ mm}^2/\text{s}$ , which approached the range of the lowest ADC inflammatory lesions. An ADC threshold of less than  $0.92 \times 10^{-3} \text{ mm}^2/\text{s}$  distinguished lymphoma from inflammation with 100% sensitivity (95% confidence interval, 92%–100%) and 100% specificity (95% confidence interval, 91%–100%).




**FIG 1.** Lesion distribution by category. The left column shows the relative proportion of lesions encountered in all published studies of orbital DWI (A), in this analysis (B), and by Shields et al<sup>1</sup> during a 30-year period (C). The published literature and our analysis group contain a higher proportion of lymphoma cases than would be predicted by Shields et al. Otherwise, the relative proportion of lesions across these 3 groups is similar, as is seen after exclusion of lymphomas (right column).

**Table 3: Descriptive statistics of orbital lesion ADC across the largest source datasets (ADC in units of  $10^{-3}$  mm<sup>2</sup>/s)**

	All Lesions (n = 183)	Sepahdari et al <sup>13</sup> (n = 50)	Politi et al <sup>17</sup> (n = 90)	Razek et al <sup>16</sup> (n = 43)
Benign lesion ADC (mean, 95% CI)	1.42 ± 0.41 (1.34–1.51)	1.36 ± 0.41 (1.22–1.51)	1.39 ± 0.42 (1.25–1.54)	1.53 ± 0.35 (1.37–1.67)
Malignant lesion ADC (mean, 95% CI)	0.90 ± 0.37 (0.83–0.98)	1.02 ± 0.42 (0.80–1.24)	0.88 ± 0.36 (0.79–0.98)	0.80 ± 0.34 (0.65–0.95)
Lymphoma ADC (mean, 95% CI)	0.67 ± 0.09 (0.64–0.69)	0.69 ± 0.16 (0.58–0.86) <sup>a</sup>	0.67 ± 0.07 (0.60–0.75)	0.67 ± 0.07 (0.60–0.73) <sup>a</sup>
Inflammatory lesion ADC (mean, 95% CI)	1.40 ± 0.31 (1.30–1.50)	1.42 ± 0.37 (1.24–1.60)	1.45 ± 0.26 (1.29–1.60)	1.24 ± 0.13 (1.18–1.33) <sup>a</sup>
Area under ROC curve (95% CI)	0.84 (0.79–0.90)	0.74 (0.58–0.89)	0.86 (0.79–0.94)	0.95 (0.87–1.0)

<sup>a</sup> The 25th–75th percentile range was reported due to a sample size too small to assume normal distribution.



**FIG 2.** Scatterplot of ADC by lesion category shows consistently low ADC for lymphoma and a wide distribution of ADC for nonlymphoma malignancies.

## DISCUSSION

This analysis showed that DWI produces equivalent quantitative ADC values across a variety of MR imaging scanners and techniques, a finding that is in concert with expectations based on previous investigation.<sup>24</sup> There were significant differences between benign and malignant lesions, though with notable overlap. ADC was highly accurate in distinguishing lymphoma from inflammatory disease.

Previous studies of orbital mass DWI have demonstrated its technical feasibility and potential clinical uses. These studies have conflicted somewhat in their results, however, and each has been limited by a retrospective, single-institution design. Therefore, the role of DWI in evaluating orbital masses remains unclear. Aggregating data from multiple institutions removes some of the selection bias inherent in the individual studies. Furthermore, this analysis verifies that quantitative ADC values are generalizable across a range of MR imaging scanners and techniques.

Previous studies have conflicted in their reports of the overall sensitivity and specificity of DWI for differentiating benign from malignant lesions and have conflicted slightly in their optimal ADC thresholds. Sepahdari et al<sup>14</sup> reported an optimal threshold value of  $1.0 \times 10^{-3}$  mm<sup>2</sup>/s for differentiating benign from malignant lesions, with an associated 63% sensitivity and 86% specificity. Razek et al<sup>16</sup> reported an optimal threshold value of  $1.15 \times 10^{-3}$  mm<sup>2</sup>/s, with a sensitivity of 95% and specificity of 91%.


Politi et al<sup>17</sup> did not specifically address the question of differentiating benign from malignant lesions, but they reported an ADC threshold of  $0.775 \times 10^{-3}$  mm<sup>2</sup>/s for distinguishing lymphoma from nonlymphoma lesions with a 96% sensitivity and 93% specificity. Roshdy et al<sup>11</sup> did not attempt to calculate a threshold ADC value and associated sensitivity and specificity, but they did note overlap between benign and malignant lesions.

The results of this multi-institutional analysis indicate that there is no single ADC threshold that is both sensitive and specific for distinguishing benign from malignant lesions. On the basis of these results, we propose a 2-threshold model for characterizing orbital masses with DWI: 1) “likely malignant,” for lesions with a >90% probability of malignancy, based on an ADC less than  $0.93 \times 10^{-3}$  mm<sup>2</sup>/s (33% of this cohort); 2) “likely benign,” for lesions with a >90% probability of benignity, based on an ADC greater than  $1.35 \times 10^{-3}$  mm<sup>2</sup>/s (29% of this cohort); and 3) “indeterminate,” for lesions with ADCs between 0.93 and  $1.35 \times 10^{-3}$  mm<sup>2</sup>/s (38% of this cohort).


In general, the optimal clinical use of DWI for evaluating an orbital mass will depend on the differential diagnosis dictated by other clinical and imaging data. For example, differentiation between lymphoma and atypical lymphocytic infiltrate or other orbital inflammatory diseases is a common diagnostic dilemma,<sup>8</sup> for which DWI proves quite useful. On occasion, it can be difficult to distinguish an infantile hemangioma (capillary hemangioma) or a vascular malformation from a rhabdomyosarcoma in a pediatric patient,<sup>25</sup> another task for which DWI would seem well-suited.<sup>21</sup> There are, however, tasks for which DWI may be limited. There was overlap in the ADC of optic nerve sheath meningioma and lymphoma, and DWI may also fail to distinguish these lesions in cases in which the imaging appearance and clinical findings overlap. The clinical and conventional imaging data should always be weighted appropriately when evaluating any single case, to ensure that the DWI information contributes to the analysis rather than detracting from it. In a practical setting, we believe that DWI is best used as a tool to further refine a short differential provided by the clinical presentation and the other imaging data.

There were 4 major limitations to this study. The first is that the data were acquired on multiple scanner types, with slight differences in acquisition technique and methods of measuring ADC. This feature is both a strength and a weakness of the study design. Although less technical standardization weakens the internal validity of the data, equivalent ADC values of similar lesions across multiple datasets suggest that quantitative ADC measurements are robust across multiple platforms. The second limitation is that some of the results may not be generalizable across all practices. The sensitivity, specificity, and accuracy of DWI in distinguishing benign from malignant lesions depend on the study population because there is heterogeneity in lesions. This study





**FIG 3.** Comparison between orbital lymphoma (A and B) and orbital inflammatory disease (C and D). A, Axial DWI shows a right orbital mass with marked hyperintensity. B, Corresponding axial ADC map shows dark signal, indicating low ADC and hypercellularity typical of lymphoma. ADC of this lesion was  $0.65 \times 10^{-3} \text{ mm}^2/\text{s}$ . C, Axial DWI in a different patient shows a lacrimal gland mass with less intense signal compared with A. D, Corresponding axial ADC map shows intermediate signal, brighter than adjacent brain parenchyma, reflective of the lower cellularity seen in orbital inflammatory lesions. The ADC of this lesion was  $1.09 \times 10^{-3} \text{ mm}^2/\text{s}$ .



**FIG 4.** Receiver operating characteristic curve analysis of ADC for distinguishing benign from malignant masses (A) shows high specificities with increasing sensitivity up to 60%, at which point additional gains in sensitivity are offset by larger losses in specificity. When lymphomas are removed from the analysis (B), the performance of ADC diminishes.

includes a larger number of patients with lymphoma and a larger proportion of lymphomas compared with other malignancies than would be expected in an unselected group of patients based on available epidemiologic data.<sup>1</sup> This fact likely improves the observed sensitivity and specificity of DWI for distinguishing benign from malignant lesions, due to the characteristic very low

ADC of lymphoma. When lymphoma lesions were removed from the analysis, the ability of DWI to differentiate benign from malignant lesions dropped. Nevertheless, there were still significant differences between benign and malignant lesions.

The results of this ad hoc subgroup analysis should be interpreted cautiously because the removal of lymphoma lesions reduces the sample size and introduces other biases. A third limitation is the inability to quantify variability in ADC measurements. A degree of intraobserver and interobserver variability in the measurement of lesion ADC is expected, and a degree of scan-to-scan variation in ADC is also expected. Without the ability to quantify these factors, it can be difficult to interpret the results of a single ADC measurement in a single patient. Overall, the effect of measurement error between or within observers on a single scan has been shown to be small,<sup>26</sup> and the variability in ADC between different scanners is similarly small.<sup>27</sup>

Finally, there are multiple areas of potential bias that could not be addressed by the study design. There may be a degree of selection bias within studies, with selective exclusion of some data points or publication bias related to exclusion of results that do not support a role for DWI. The exclusion of published studies for which ADC values could not be obtained could also affect the results. Note that 2 lymphomas and 3 rhabdomyosarcomas reported by Roshdy et al<sup>11</sup> showed higher average ADC than was observed in our group but were excluded because the ADC data were reported as an average. Specifically, Roshdy et al reported 2 lacrimal gland lymphomas whose average ADC overlapped that in the inflammatory lesions we observed. Our study may therefore overestimate the true performance of DWI in distinguishing lymphoma from inflammatory disease.

## CONCLUSIONS

This analysis of multi-institutional data confirms that benign and malignant orbital tumors have significant differences in ADC. There was no single ADC threshold that was both highly sensitive and specific for predicting malignancy. On the basis of these results, we propose a “likely malignant” threshold ADC of  $<0.93 \times 10^{-3} \text{ mm}^2/\text{s}$ , a “likely benign” threshold ADC of  $>1.35 \times 10^{-3} \text{ mm}^2/\text{s}$ , and an “indeterminate range” ADC be-

**Table 4: Sensitivity and specificity of various ADC threshold values for distinguishing benign from malignant lesions**

ADC ( $10^{-3}$ mm <sup>2</sup> /s)	Sensitivity (%)	Specificity (%)	Likelihood Ratio of Positive Results
0.72	40	99	39
0.82	54	97	17
0.93	60	96	14
1.03	67	85	4.3
1.13	77	77	3.4
1.23	80	66	2.3
1.33	89	54	1.8
1.42	92	41	1.6
1.52	93	34	1.4

tween 0.93 and  $1.35 \times 10^{-3}$  mm<sup>2</sup>/s when evaluating orbital masses with DWI. Knowledge of the expected ADC values of common lesions may also be helpful in organizing the differential diagnosis determined by other clinical and imaging data. DWI may be particularly helpful in distinguishing inflammatory disease from lymphoma.

### ACKNOWLEDGEMENTS

We would like to thank Dr. Sahar M. Elkhamary, of King Khaled Eye Specialist Hospital and Mansoura University Faculty of Medicine, for providing data for this study.

### REFERENCES

- Shields J, Shields C, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions. 1. The 2002 Montgomery Lecture, part 1. *Ophthalmology* 2004;111:997–1008
- Mafee M, Karimi A, Shah J, et al. Anatomy and pathology of the eye: role of MR imaging and CT. *Neuroimaging Clin North Am* 2005;15:23–47
- Mafee MF, Edward DP, Koeller KK, et al. Lacrimal gland tumors and simulating lesions: clinicopathologic and MR imaging features. *Radiol Clin North Am* 1999;37:219–39, xii
- Mafee MF, Goodwin J, Dorodi S. Optic nerve sheath meningiomas: role of MR imaging. *Radiol Clin North Am* 1999;37:37–58, ix
- Mafee MF, Dorodi S, Pai E. Sarcoidosis of the eye, orbit, and central nervous system: role of MR imaging. *Radiol Clin North Am* 1999;37:73–87, x.
- Valvassori GE, Sabnis SS, Mafee RF, et al. Imaging of orbital lymphoproliferative disorders. *Radiol Clin North Am* 1999;37:135–50, x–xi
- Carroll GS, Haik BG, Fleming JC, et al. Peripheral nerve tumors of the orbit. *Radiol Clin North Am* 1999;37:195–202, xi–xii
- Akansel G, Hendrix L, Erickson BA, et al. MRI patterns in orbital malignant lymphoma and atypical lymphocytic infiltrates. *Eur J Radiol* 2005;53:175–81
- Smoker WR, Gentry LR, Yee NK, et al. Vascular lesions of the orbit: more than meets the eye. *Radiographics* 2008;28:185–204, quiz 325
- Razek AA. Diffusion-weighted magnetic resonance imaging of head and neck. *J Comput Assist Tomogr* 2010;34:808–15

- Roshdy N, Shahin M, Kishk H, et al. MRI in diagnosis of orbital masses. *Curr Eye Res* 2010;35:986–91
- Kapur R, Sepahdari AR, Mafee MF, et al. MR imaging of orbital inflammatory syndrome, orbital cellulitis, and orbital lymphoid lesions: the role of diffusion-weighted imaging. *AJNR Am J Neuro-radiol* 2009;30:64–70
- Sepahdari AR, Kapur R, Aakalu VK, et al. Diffusion-weighted imaging of malignant ocular masses: initial results and directions for further study. *AJNR Am J Neuroradiol* 2012;33:314–19
- Sepahdari AR, Aakalu VK, Setabutr P, et al. Indeterminate orbital masses: restricted diffusion at MR imaging with echo-planar diffusion-weighted imaging predicts malignancy. *Radiology* 2010;256:554–64
- Sepahdari AR, Aakalu VK, Kapur R, et al. MRI of orbital cellulitis and orbital abscess: the role of diffusion-weighted imaging. *AJR Am J Roentgenol* 2009;193:W244–50
- Razek AA, Elkhamary S, Mousa A. Differentiation between benign and malignant orbital tumors at 3-T diffusion MR-imaging. *Neuro-radiology* 2011;53:517–22
- Politi LS, Forghani R, Godi C, et al. Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring. *Radiology* 2010;256:565–74
- de Graaf P, Pouwels PJ, Rodjan F, et al. Single-shot turbo spin-echo diffusion-weighted imaging for retinoblastoma: initial experience. *AJNR Am J Neuroradiol* 2012;33:110–18
- Srinivasan A, Dvorak R, Perni K, et al. Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. *AJNR Am J Neuroradiol* 2008;29:40–44
- Maeda M, Kato H, Sakuma H, et al. Usefulness of the apparent diffusion coefficient in line scan diffusion-weighted imaging for distinguishing between squamous cell carcinomas and malignant lymphomas of the head and neck. *AJNR Am J Neuroradiol* 2005;26:1186–92
- Lope LA, Hutcheson KA, Khademian ZP. Magnetic resonance imaging in the analysis of pediatric orbital tumors: utility of diffusion-weighted imaging. *J AAPOS* 2010;14:257–62
- Yang BT, Wang YZ, Dong JY, et al. MRI study of solitary fibrous tumor in the orbit. *AJR Am J Roentgenol* 2012;199:W506–11
- Kamano H, Noguchi T, Yoshiura T, et al. Intraorbital lobular capillary hemangioma (pyogenic granuloma). *Radiat Med* 2008;26:609–12
- Chenevert TL, Galbán CJ, Ivancevic MK, et al. Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. *J Magn Reson Imaging* 2011;34:983–87
- Chung EM, Specht CS, Schroeder JW. From the archives of the AFIP: pediatric orbit tumors and tumorlike lesions: neuroepithelial lesions of the ocular globe and optic nerve. *Radiographics* 2007;27:1159–86
- Bilgili Y, Unal B. Effect of region of interest on interobserver variance in apparent diffusion coefficient measures. *AJNR Am J Neuro-radiol* 2004;25:108–11
- Sasaki M, Yamada K, Watanabe Y, et al. Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. *Radiology* 2008;249:624–30